159 results about "Hyperlipemias" patented technology

The present invention provides methods for treating patients suffering from familial hypercholesterolemia, including both HeFH and HoFH. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to ANGPTL3 in combination with a therapeutically effective amount of a statin, a first lipid lowering agent other than a statin, and a second lipid lowering agent other than a statin. The first non-statin lipid lowering agent is an agent that inhibits cholesterol uptake (e.g. ezetimibe) and the second non-statin lipid-lowering agent is an inhibitor of microsomal triglyceride transfer protein (e.g. lomitapide). The combination therapy is useful in treating hypercholesterolemia, as well as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.

The invention relates to N-fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid or a pharmaceutical composition and application thereof, and relates to the technical field of biological medicines. According to the application disclosed by the invention, the N-fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid is found to have the effects of reducing total cholesterol, triglyceride and low-density lipoprotein cholesterol in serum and increasing high-density lipoprotein cholesterol in serum for the first time; the compound can be used for preparing a medicine for reducing total cholesterol in serum, a medicine for reducing triglyceride in serum, a medicine for reducing low-density lipoprotein cholesterol in serum and a medicine for increasing high-density lipoprotein cholesterol in serum, and can be used for preparing medicines for reducing total cholesterol in serum, triglyceride in serum, low-density lipoprotein cholesterol in serum and high-density lipoprotein cholesterol in serum. And an effective new means and a new way are provided for preparing the medicine for preventing or treating the hyperlipemia.

The invention relates to an shRNA (short hairpin Ribonucleic Acid) interference sequence of a targeted silence PCSK9 gene and a construction method and lipid-lowering application of a recombinant adeno-associated virus vector of the shRNA interference sequence. Hyperlipidaemia is a metabolic disease characterized by abnormal rising of cholesterol and triglyceride levels in blood, and the design of lipid-lowering drugs is the focus of attention to improvement of hyperlipidaemia. Proprotein convertase subtilisin / kexin type 9 (PCSK9) can be combined with a low-density lipoprotein receptor (LDL-R) and degrade the LDL-R, so that accumulation of LDL-C in blood is further promoted, and hyperlipidemia is caused. Aiming at the key target PCSK9, a specific shRNA interference sequence is designed, and a recombinant adeno-associated virus vector (rAAV) carrying the sequence is constructed by an enzyme digestion-connection method. In-vitro experiments prove that the vector can remarkably reduce the expression level of PCSK9 protein, so that the cyclic utilization of a low-density lipoprotein receptor (LDL-R) is promoted, and the concentration of low-density lipoprotein cholesterol (LDL-C) in plasma is reduced. The rAAV vector provided by the invention has the characteristics of low production cost, high transfection efficiency, lasting action time and the like, and provides a new thought for gene therapy of hyperlipidemia.

The present invention relates to the field of traditional Chinese medicine technology, and in particular to a Chinese medicine composition, granule preparation and preparation method thereof for treating carotid atherosclerosis combined with hyperlipidemia. The Chinese medicine composition for treating carotid atherosclerosis combined with hyperlipidemia is mainly prepared from the following components in parts by weight: 8-12 parts of Chuanxiong, 8-12 parts of red peony root, 3-7 parts of coptis root, 8-12 parts of red yeast rice and 3-7 parts of roasted liquorice. The Chinese medicine composition provided by the present invention can have good therapeutic effects on the patient group with carotid atherosclerosis combined with hyperlipidemia, which is a common and frequently occurring disease in the field of cardiovascular disease prevention and treatment. In addition, the present invention prepares the Chinese medicine composition into a granule preparation in a certain manner, ensuring the molding rate, solubility rate, bulk density, angle of repose and moisture absorption rate of the preparation, thereby ensuring the efficacy of the preparation, extending the storage time of the product, taking into account the patient's acceptance, and easily realizing large-scale production.

The present invention relates to use of an anti-ANGPTL3 antibody in treating hyperlipidemia and a method. Specifically, the present invention relates to use of an anti-ANGPTL3 antibody or an antigen-binding fragment thereof in preparing a drug for treating hyperlipemia patients, wherein the hyperlipemia patients are subject to the risk of atherosclerosis cardiovascular disease.

The invention provides vinasse dietary fiber with blood fat reducing activity and a preparation method of the vinasse dietary fiber. The vinasse dietary fiber with relatively high purity is obtained by performing alkali soaking, sodium chlorite bleaching, crushing and drying on the vinasse. The prepared vinasse dietary fiber can effectively improve hyperlipidemia of obese diabetes model mice, reduce triglyceride and total cholesterol levels of serum and liver and improve liver injury, and can be applied to preparation of functional food, health care products, medicines and feeds with the blood glucose reducing effect.

The application discloses a construction method of a fat-targeted gene therapy vector. The method comprises the following steps: obtaining a fat tissue-specific promoter sequence; obtaining a shRNA coding sequence targeting a Tks4 gene; cloning the promoter sequence and the shRNA coding sequence into an adeno-associated virus vector skeleton to construct a recombinant expression vector; and co-transfecting the recombinant expression vector and an auxiliary plasmid into a packaging cell to package and purify a recombinant adeno-associated virus particle. The vector constructed by the application adopts an adiponectin promoter to drive the expression of miR30-shRNA targeting the Tks4, and can be specifically expressed in fat tissues and livers after being injected through a tail vein, significantly inhibits fat cell hypertrophy and systemic fat accumulation induced by a high-fat diet, reduces the serum cholesterol level, does not cause an immune inflammatory reaction, does not affect sugar metabolism, and is not expressed in non-target tissues. The application provides a safe and efficient new strategy for the gene therapy of obesity, hyperlipidemia, fatty liver and related metabolic diseases.

The invention provides a lipid-lowering traditional Chinese medicine composition and extract as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The lipid-lowering traditional Chinese medicine composition is prepared from the following raw materials: rhizoma cyperi and radix gentianae. The invention further provides an extract of the lipid-lowering traditional Chinese medicine composition. The extract is obtained by mixing rhizoma cyperi and radix gentianae and then co-extracting. The composition or the extract can be used for preparing medicines for preventing and / or treating hyperlipemia, and can be used for improving lipid metabolism disorder of liver cells and reducing the content of triglyceride and total cholesterol in the liver cells.

The present disclosure relates to methods of administering thyroid hormone receptor agonists. The present disclosure provides methods wherein the methods maintain the activity of a given thyroid receptor agonist in ameliorating or curing obesity, hyperlipidemia, hypercholesterolemia, diabetes, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, hypothyroidism, and related conditions, meanwhile, thyroid-related and thyroid axis-related side effects are reduced or eliminated.

The invention belongs to the technical field of medicine, and particularly relates to application of northern swertia extract in preparation of medicine for preventing or treating metabolic diseases, the metabolic diseases comprise at least one of obesity and hyperlipidemia, and the northern swertia extract is alcohol extract of northern swertia or is prepared by supercritical CO2 extraction of northern swertia. When the swertia northern extract is used for treating obesity, hyperlipidemia, non-alcoholic fatty liver and other metabolic diseases, the diversity of intestinal flora can be regulated and controlled, the abundance of beneficial bacteria is improved, bile acid metabolism is promoted, and in-vivo lipid metabolism is promoted.

The present invention relates to a combination of Chinese and Western medicines for treating hyperlipidemia. In particular, the present invention relates to a pharmaceutical combination of probucol and red yeast rice, a pharmaceutical composition or a kit comprising probucol and red yeast rice, and the use of the pharmaceutical combination, pharmaceutical composition or kit in preparing a medicament for treating hyperlipidemia, particularly severe hypertriglyceridemia and severe hypercholesterolemia. The present invention is characterized in that the pharmaceutical combination, pharmaceutical composition or kit comprising probucol and red yeast rice comprises a small dose of probucol and red yeast rice, and the probucol and red yeast rice are configured for simultaneous administration.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a turbidity-dissolving and lipid-lowering composition and a preparation method thereof.The composition comprises 80-130 parts of polygonum cuspidatum, 50-90 parts of fried semen cassiae, 100-140 parts of hawthorn, 50-90 parts of rhizoma alismatis, 10-60 parts of rhizoma atractylodis macrocephalae fried with bran and 50-90 parts of rhizoma wenyujin concisum. The composition disclosed by the invention has the effects of eliminating phlegm, dissolving turbidity, promoting blood circulation to remove blood stasis, invigorating stomach and promoting diuresis, can be used for treating hyperlipidemia, hyperviscosity and arteriosclerotic cardia-cerebrovascular diseases, and has a very good application prospect.

Compositions and method of increasing levels of apoA1 and / HDL in a subject in need thereof are provided. The compositions include one or more TLR5 agonists in a pharmaceutically acceptable carrier in an effective amount to increase the level of apoA1 and / or HDL in a subject. In a preferred embodiment, the composition is an oral formulation of the one or more TLR5 agonists. The disclosed methods include administering compositions containing the one or more TLR5 agonists to a subject in need thereof, in an effective amount to increase levels of apoA1 and / or HDL in the subject. In one preferred embodiment, the subject is at risk of developing atherosclerosis and / or coronary heart disease. In some embodiments, the subject is diagnosed as having atherosclerosis. The disclosed compositions can also be administered to subjects presenting with hyperlipidemia or hypercholesterolemia.

The invention relates to the technical field of biological medicines, and discloses application of INHBC as a target spot in prevention and / or treatment of metabolic diseases. Specifically, the invention relates to application of substances for promoting INHBC gene expression or improving protein activity in preparation of products for preventing and / or treating metabolic diseases, and the metabolic diseases comprise diseases caused by energy metabolism disorder, such as obesity, diabetes, fatty liver disease, hyperlipidemia and the like. According to the application disclosed by the invention, liver specific overexpression or INHBC knock-in can improve mouse liver fatty degeneration and abnormal glucose metabolism induced by high fat diet, and in addition, the heat production activity of mouse adipose tissues can be enhanced, so that obesity induced by high fat diet is inhibited; the compound has an important application value in preventing and / or treating metabolic diseases such as obesity, type 2 diabetes and fatty liver diseases.

The present invention relates to use of a GLP-1R / GLP-2R dual agonist, namely dapiglutide, for reducing cholesterol, in particular total cholesterol (TC) and low-density lipoprotein cholesterol (LDL cholesterol). The invention also relates to dapiglutide for treatment of hyperlipidaemia, in particular hypercholesterolaemia.

This invention relates to extracts of traditional Chinese medicine, and particularly to the application of a compound extract with lipid-regulating effects in the preparation of lipid-regulating drugs. Experimental studies of this invention have found that a compound traditional Chinese medicine lipid-regulating formula, administered for 14 weeks, can effectively reduce serum total cholesterol levels in hyperlipidemic mice. Furthermore, the lipid-lowering effects of the compound formula at 7.08 g / kg (high-dose group) and 3.54 g / kg (low-dose group) in hyperlipidemic mice are similar to those of simvastatin. Moreover, the dosage of the lipid-regulating compound formula is lower. This important compound lipid-regulating formula described in this invention can be applied to the prevention and treatment of hyperlipidemia, providing a new option for the prevention and treatment of hyperlipidemia.

The present invention provides a pharmaceutical composition comprising a) a first phase comprising rosuvastatin, and b) a second phase comprising acetylsalicylic acid, wherein the first phase comprising rosuvastatin is in the form of a coated tablet, and the second phase comprising acetylsalicylic acid is in the form of granules; said pharmaceutical composition solves a set of significant technological challenges due to the physicochemical properties and difference in dosage of each drug. The pharmaceutical composition of the present invention is stable, and also has a comparative bioavailability equivalent to that of the co-administered monodrugs, so that the composition is safe and effective in the treatment of hyperlipidemias and in the prevention of at least one cardiovascular disease. The invention is also directed to a process for manufacturing the pharmaceutical composition.

The invention discloses a biomarker for diagnosing obesity and complications thereof and application of the biomarker. The biomarker is one or a combination of more of ADAM8, FASN and ELOVL6. The invention also provides a kit for diagnosing obesity and complications thereof. The kit comprises a reagent for detecting the expression level of one or more proteins of ADAM8, FASN and ELOVL6. According to the present invention, the expression levels of ADAM8, FASN and ELOVL6 in serum are detected by using the ELISA kit, such that the sensitivity and the specificity are high. The method is easy and convenient to operate and accurate in result, early diagnosis and intervention of obesity-related hyperlipemia are facilitated, and the burden of patients and the society is relieved.

The application relates to the field of biological medicine, and particularly discloses Creld2 as a biomarker of atherosclerosis. For the first time, the Creld2 level of mouse models of obesity, diabetes, hyperlipidemia and atherosclerosis is detected, and it is found that the serum Creld2 level is greatly increased only when atherosclerosis occurs. The increase of the Creld2 level is related to the development process of atherosclerosis, and with the aggravation of atherosclerotic plaques, the serum Creld2 level is further increased. The serum Creld2 level of the atherosclerosis model group is greatly increased compared with the normal control group, and the Creld2 level ranges of the two groups do not overlap, so that the Creld2 is taken as the biomarker of atherosclerosis and has high diagnostic efficiency, can be used as an early blood diagnostic marker of atherosclerosis, is beneficial to low-cost, large-scale screening and monitoring, can be used for early diagnosis and treatment of atherosclerosis, and improves the life quality of patients.

This invention relates to *Lactobacillus paracasei* NEFU-5 and its applications, belonging to the field of biotechnology. To address the problems of limited functionality and poor direct degradation of metabolites in existing probiotic strains, this invention provides *Lactobacillus paracasei* NEFU-5 (accession number CCTCC NO: M 2026147). This *Lactobacillus paracasei* NEFU-5 can simultaneously and efficiently degrade uric acid, triglycerides, and cholesterol, and possesses excellent probiotic properties and safety. The *Lactobacillus paracasei* NEFU-5 provided by this invention can be used to prepare fermented products and can be used to prevent or improve hyperuricemia, hyperlipidemia, and other concurrent metabolic diseases, showing significant application prospects.

The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor for use in the treatment of a subject suffering from or at an increased risk of cardiovascular disease, in particular hyperlipidemia or mixed dyslipidemia. Another aspect of the invention relates to a pharmaceutical composition for treating a subject suffering from or having an increased risk of cardiovascular disease, wherein the composition comprises a therapeutically effective amount of the CETP inhibitor.

The invention provides a traditional Chinese medicine composition for treating hyperlipemia, a pharmaceutical preparation and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following components: rhizoma atractylodis macrocephalae, radix salviae miltiorrhizae, radix notoginseng, radix astragali seu hedysari, radix puerariae, fructus crataegi, salted rhizoma alismatis, concha haliotidis and raw malt. The traditional Chinese medicine composition and the medicinal preparation provided by the invention have the effects of replenishing qi to invigorate the spleen, and promoting diuresis and reducing phlegm, can be used for both purgation and tonification and combining phlegm and blood stasis, and can be used for treating hyperlipemia, especially hyperlipemia caused by insufficiency of the spleen and excessive dampness.

Disclosed are compounds of Formula I as well as pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.

The present invention relates to the method for obtaining in pure form or as a mixture of the bioactive diol forms of the main secoiridoid phenols present in olive oil and certain isomeric forms or derivatives thereof. Specifically, it relates to the production process of S-(E)-oleocanthadiol, S-(E)-oleaceinediol, 5S-(E)-oleomissionadiol, 5S-(E)-oleokoronadiol, oleuropeinediol and ligstrodiol and their corresponding polyethylene glycol hemiacetals through extraction of specifically selected olive oil with polyethylene glycol and then treated with water. It also relates to the pharmaceutical preparations containing the above substances in various combinations and the therapeutic properties of these preparations for the treatment of cancer, degenerative diseases of the central nervous system, diabetes, hyperlipidemia, inflammatory diseases and the prevention of creation of atherosclerotic plaques and thrombi.

This invention belongs to the field of pharmaceutical technology, specifically relating to the use of a 4-(4-diethylamino-1-methylbutanamino)-7-chloroquinoline derivative or its pharmaceutically acceptable salt, or its tautomer, meso compound, racemic compound, enantiomer, diastereomer, or pharmaceutical composition thereof as an active ingredient in the preparation of drugs for the prevention or treatment of obesity and obesity-related metabolic diseases. The 4-(4-diethylamino-1-methylbutanamino)-7-chloroquinoline derivative of this invention has significant therapeutic effects on obesity and related metabolic diseases. In obese mice induced by a high-fat diet and high-fructose water intake, gavage administration for 6 weeks showed that, compared with the high-fat control group, it inhibited more than 70% of the mice's weight gain, with no significant difference in food intake and water intake, demonstrating good clinical application prospects.

The invention provides compound essential oil of bastardwood and application of the compound essential oil in preparation of products for preventing and treating hyperlipidemia, and relates to the technical field of traditional Chinese medicine essential oil. The traditional Chinese medicine compound essential oil is prepared from radix morindae officinalis essential oil, rhizoma coptidis essential oil and radix aucklandiae essential oil. The traditional Chinese medicine compound essential oil can significantly reduce the weight gain trend of a hyperlipidemia mouse model, reduce the weight of the mouse, effectively reduce the triglyceride, cholesterol and LDL level in serum and liver of the hyperlipidemia mouse model, improve the HDL level, significantly improve the hyperlipidemia symptom of the model mouse, and achieve the purpose of regulating lipid metabolism; meanwhile, liver fatty degeneration can be inhibited, the diameter of fat cells is reduced, and the traditional Chinese medicine compound essential oil has huge application potential in treatment or prevention of hyperlipidemia.

1. Name of the product in this design: Playing cards (Diet for patients with hyperlipidemia and pancreatitis). 2. Purpose of this design: For use in playing card entertainment products. 3. The key design elements of this product are the combination of shape, pattern, and color. 4. The image or photograph that best illustrates the design highlights: Component 1 main view. 5. The design for which protection is sought includes color. 6. This design is for a thin product, and the left, right, top, and bottom views of components 1 to 54 are omitted.

The application belongs to the technical field of biological medicine, and discloses a novel polypeptide with lipid-lowering effect. In view of the problem that polypeptides are prone to be enzymolyzed in the gastrointestinal tract and difficult to play obvious effect in the body, a novel polypeptide is designed, and the amino acid sequence of the polypeptide is GQAIWMY. The polypeptide GQAIWMY has lipid-lowering capacity, is not prone to be degraded by gastrointestinal enzymes and is more stable, and can be used for preparing drugs for preventing or treating cardiovascular diseases (such as hyperlipidemia, atherosclerosis, coronary heart disease) and fatty liver diseases.

The invention belongs to the technical field of functional microorganism application, and particularly relates to a novel lipid-lowering peptide derived from a probiotic thallus and application thereof, the novel lipid-lowering peptide is a crushed substance derived from a probiotic lactobacillus plantarum thallus, and the molecular weight of the novel lipid-lowering peptide is less than 3kDa. And two key polypeptides APGFGDR (AP7) and TESGAFGR (TE8) are identified from the components, and can specifically inhibit the activities of pancreatic lipase and pancreatic cholesterol esterase. The extracted thallus peptide can be efficiently combined with cholate to inhibit the formation of cholesterol micelles, and has a remarkable inhibiting effect on pancreatic lipase and pancreatic cholesterol esterase. Animal experiments show that the mycopeptide can effectively improve lipid metabolism disorder induced by high fat diet, inhibit weight gain, reduce serum and liver lipid levels and relieve fatty degeneration and inflammation of the liver. The lipid-lowering peptide disclosed by the invention is high in safety and multi-target in action, and can be used for preparing functional products for preventing or treating metabolic diseases such as obesity, hyperlipidemia and the like.

The application discloses 3-substituted coumarin derivatives 1a-14a and symmetrical biscoumarin derivatives 1b-25b and pharmaceutically acceptable salts, solvates or hydrates thereof. The compounds provided by the application are specific inhibitors of ATP citrate lyase (ACLY), and the half maximal inhibitory concentration (IC 50 ) of the former is 2-30 muM, and the IC 50 ) of the latter is 0.065-4 muM, so the compounds have potential therapeutic value for a plurality of diseases with abnormally high expression of ACLY, such as cancer, hyperlipidemia and arteriosclerotic cardiovascular diseases.